Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics Inc. is experiencing a positive outlook driven by an increase in its modeled peak market penetration for cadisegliatin (TTP399) to 25%, reflecting enhanced confidence in its risk-adjusted DCF valuation. The management has reported promising progress in the CATT1 study, which bolsters faith in the drug's ongoing development and its potential impact in providing an innovative oral therapy for type 1 diabetes patients. Furthermore, the strategic position of cadisegliatin as the only oral adjunctive therapy in late-stage development for T1D highlights its competitive advantage in a market burdened by existing injection methods, paving the way for significant commercial potential.

Bears say

vTv Therapeutics's stock faces a negative outlook primarily due to challenges with its lead candidate, cadisegliatin (TTP399), which remains in late-stage development and is subject to clinical risks such as slower patient enrollment and potential safety and efficacy concerns that may not align with earlier study results. Historical data indicates significant setbacks with first-generation glucokinase activators, including issues related to hypoglycemia and diminishing glycemic benefits over time, which could foreshadow similar problems for TTP399. Additionally, the context of nearly 80% of adults with type 1 diabetes failing to meet the American Diabetes Association's A1C threshold highlights the difficulties in achieving effective glucose control, thereby raising doubts about the commercial viability of vTv Therapeutics's pipeline.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.